Navigation Links
Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia
Date:6/14/2010

e 28465583. The presentation will be available via webcast at:

http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=197259&eventID=3135083

A replay of the call will be available from 11:30 AM ET on June 15, 2010 until midnight on June 22, 2010. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 87529369. The archived webcast will be available for 30 days in the Investor Relations section of the Micromet website at www.micromet-inc.com.

About Blinatumomab

Blinatumomab (MT103) is a novel, next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of B-cell derived acute lymphoblastic leukemias and non Hodgkin's lymphomas. Micromet received orphan drug designation from the European Medicines Agency for blinatumomab for the treatment of acute lymphoblastic leukemia, mantle cell lymphoma and chronic lymphatic leukemia and from the Food and Drug Association for the treatment of acute lymphoblastic leukemia, chronic lymphocytic leukemia, indolent B cell lymphoma, hairy cell leukemia and prolymphocytic leukemia.

About Acute Lymphoblastic Leukemia'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
2. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
4. Newly Updated Pharmacy State Law Compendium Available
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
6. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
7. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
8. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
9. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
10. ORTHO EVRA(R) Prescribing Information Updated
11. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for operable and inoperable solid tumor cancers, ... at the 7 th Annual Phacilitate Immunotherapy Forum in ... presentation at Phacilitate will take place on January 26 at ...
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... TAMPA, Fla. , Jan. 23, 2015  iMD Companies, Inc. ... plan to increase market share and grab a foothold in ... with influence, production capabilities and a presence in the sector, ... them facilitate the growth of hemp and medical marijuana, iMD ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... January 22, 2015 For over 20 years, Dr. ... Oceanside and Vista area has treated just about every type ... injury circumstances. And for those same twenty-plus years, the team ... all those injuries with the best possible doctor. With ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... 2015 IsoComforter, Inc. has introduced the most ... IsoTube design to treat specific body parts and muscle groups. ... and easy to use patented cold therapy machine with the ... orthopedic and muscle injuries. IsoComforter has become the industry ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... sales in the first half of Craneware,s 10th Anniversary YearATLANTA, Feb. ... improvement software for hospitals and health systems, is pleased to announce ... Highlights , , ... (H108: $12.9m) contributing to: , ...
... Hall to be Board Chairman; Siegrist Takes on Executive PostSOUTH ... announced his decision to transition from president and chief executive ... Inc., effective March 16. Rick Siegrist, M.B.A., president of a ... member of the Press Ganey Board of Directors, will take ...
... U.S. Department of Labor,s Occupational Safety and Health Administration ... Co., doing business as Ro-Corp Inc., for alleged willful, ... proposing more than $1.2 million in penalties for numerous ... the company,s facility in East St. Louis.OSHA began an ...
... The following was released today by SEIU UHW: NOTE TO ... expected to reach Congress--several hundred SEIU members from around the ... president,s vision to fix healthcare. The rally will be held at ... noon. California Healthcare for America Now (HCAN) ...
... disease severity, experts say, , , WEDNESDAY, Feb. 25 ... gene associated with cystic fibrosis. , Dr. Christopher ... and an international team of colleagues demonstrated that ... the airway disease that marks cystic fibrosis (CF) ...
... A newly released joint guideline produced by the American ... Association (AUA) recommends that healthy men who are screened ... the disease should talk to their doctors about using ... 5-ARIs lower the level of the hormone dihydrotestosterone (DHT), ...
Cached Medicine News:Health News:Craneware Announces Half-Year Results 2Health News:Changing of the Guard at Press Ganey 2Health News:Changing of the Guard at Press Ganey 3Health News:U.S. Department of Labor's OSHA proposes more than $1.2 million penalty to St. Louis area chemical repackaging and distribution company 2Health News:L.A. Area SEIU Members Gear Up to Support Effort to Fix Healthcare; Plan Rally for Thursday 2Health News:Study Pinpoints New Gene for Cystic Fibrosis 2Health News:Study Pinpoints New Gene for Cystic Fibrosis 3Health News:New ASCO/AUA guideline recommends men and their doctors discuss using 5-ARIs to reduce prostate cancer risk 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: